The source of investor bearishness in previous days was Hims & Hers' announcement on Monday that it might halt sales of a highly popular product -- compound versions of semaglutide, the white-hot ...

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Novo Nordisk’s Wegovy and Ozempic has been resolved.